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Abstract 
Safe prescribing of combined hormonal contraceptives is important to prevent unplanned 
pregnancies and adverse effects including thrombotic events. Combined hormonal contraceptives 
can be taken safely but this relies on appropriate prescribing techniques by the healthcare 
provider. Prior to prescribing any type of contraception, health care providers should perform a 
risk assessment to anticipate and prevent patient complications. The Centers for Disease Control 
and Prevention created the United States Medical Eligibility Criteria (U.S. MEC) for 
contraceptive use guideline to help direct healthcare providers to assess patient risk factors, 
prescribe the safest form of contraception, and provide necessary teaching and follow-up. This 
project includes a retrospective chart audit of 100 charts from university-based, outpatient, 
primary care clinics to examine contraceptive counseling and prescribing behaviors and compare 
these with the recommendations set forth by the guideline. This project will help identify 
guideline adherence and specifically assess prescriber documentation of risk factors associated 
with combined contraceptives, the safety of prescribing a combined hormonal contraceptive, and 
prescriber documentation of combined contraceptive counseling and follow-up.  
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Introduction 
 My sister-in-law was 21 when a pulmonary embolism threatened her life. The cause was 
attributed to combined hormonal contraceptive (CHC) use and she expressed feelings of 
resentment. She felt cheated that her providers never educated her regarding the serious risks of 
CHC use. At the time, my sister-in-law was by definition obese with undiagnosed hypertension, 
however, she would have chosen a different contraceptive method had she known about the risk 
of a thrombotic event. Like many women, the ease and convenience of the birth control pill drew 
her to choose the pill, despite other and potentially safer techniques to prevent unintended 
pregnancy. The purpose of this paper is to examine CHC prescribing to identify barriers of unsafe 
practices.  
Background 
 Unplanned pregnancies contribute to a significant health disparity in the United States 
(US). In the US, unplanned pregnancies make up approximately half (51%) of all pregnancies 
and 40% of unintended pregnancies result in abortions (Finer & Zolna, 2014). Additionally, 
unintended pregnancies cost taxpayers nine billion U.S. dollars per year (Finer & Henshaw, 
2006; Hoffman, 2006). Compared with the rest of the world, North America is the only continent 
in the world where rates of unplanned pregnancies are consistent or increasing over the past 
decade (Singh, Sedgh, & Hussain, 2010). Unplanned pregnancies also create health disparities 
for mothers and children affected.  
Unintended pregnancies negatively impact the physical and psychological health of mom 
and baby. Unplanned pregnancies are associated with preterm birth, low birth weight (Shah et 
al., 2011), tobacco use during pregnancy, and late prenatal care (David, 2006; Logan, Holcombe, 
Manlove, & Ryan, 2007). Furthermore, infants of unplanned pregnancies are less likely to be 
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breastfeed and are more likely to have poorer health outcomes during childhood (Taylor & 
Cabral, 2002). Female babies born from unplanned pregnancies are more likely to have 
unplanned pregnancies themselves and male babies are more likely to experience incarceration 
later in life (Elfenbein & Felice, 2003). Mothers with unintended pregnancies also face 
challenges and are prone to depression and intimate partner violence, and are less likely to 
complete high school by age 22 (Logan, Holcombe, Manlove, & Ryan, 2007). Given these 
serious consequences, global leaders advocated for prevention of unplanned pregnancies. 
In 2015, the World Health Organization (WHO) identified access to safe and effective 
contraception as a worldwide public health goal. To accomplish this goal, the U.S. Department 
of Health and Human Services focused on contraceptive counseling and family planning using 
the Healthy People 2020 objectives (Office of Disease Prevention and Health Promotion, 2014). 
Healthy People objectives identify chief health indicators that address health disparities, 
including promotion of family planning and reproductive health among females (Office of 
Disease Prevention and Health Promotion, 2014). For example, one objective in 2002 was to 
decrease unplanned pregnancies from 49% to 44% and increase contraceptive use at last 
intercourse from 83% to 92%. (Centers for Disease Control and Prevention, 2011). Preventing 
unplanned pregnancies by advocating for contraceptive use was not a simple solution. Although 
contraception use is effective at preventing unplanned pregnancies, the WHO goal of 
contraceptive safety is a concern.  
Problem 
Since the release of oral contraception, complications became associated with CHCs 
including venous thromboembolism (Piparva & Buch, 2011). Combined hormonal 
contraceptives include both estrogen and progesterone hormones, and pill, patch, and vaginal 
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ring methods. A venous thromboembolism (VTE) is a clot and can come in the form of a deep 
vein thrombosis (DVT) or pulmonary embolism (PE) and both are life-threatening as the 
thrombus can migrate into the arterial system resulting in stroke and heart attack (Hee, Kettner, 
& Vejtorp, 2013). If death is not the end result, quality of life is significantly and permanently 
impacted.  
Although CHC related VTE events are arguably rare, the increased chance of PE, stroke, 
or heart attack among young women who use CHC is nonetheless a tragic consequence. Oral 
contraceptive pill users, especially those with certain risk factors and who use CHCs, are two to 
six times more likely to develop a VTE when compared to those who do not use the pill (Doma, 
Vucnik, Mijovski, Peternel, & Stegnar, 2013). In a systematic review and meta-analysis of 26 
studies, CHC users were three to four times more likely to be diagnosed with a VTE compared 
with non-users (De Bastos et al., 2014). In a case-control study of 186 young women with 
diagnosis of VTE, 23% were CHC related (Westhoff, Yoon, Tang, Pulido, & Eisenberger, 2016). 
Finally, it is estimated that a new user of CHC increases her annual VTE risk from 4.5 to 14.5 
per 10,000 woman-years (Manzoli, De Vito, Marzuillo, Boccia, & Villari, 2012). The increased 
risk, while small, still deserves prevention techniques.  
Due to the importance of VTE prevention, it is recommended that both patients and health 
care providers communicate about contraceptive risk factors prior to CHC use. The American 
College of Obstetricians and Gynecologists (2012) recommended that prior to prescribing any 
type of CHC, health care providers perform a risk assessment to anticipate and prevent patient 
complications by communicating contraceptive risks (Vogt & Scheafer, 2011). The most notable 
CHC related VTE risks are age and smoking, and the FDA cautioned prescription of CHCs to 
women who smoke and are 35 years and older (World Health Organization, 2015). In addition to 
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age and smoking status, other conditions that predispose CHC users to VTE are the postpartum 
period (40–65 per 10,000 woman-years; Food and Drug Administration, 2012), recent surgery, 
migraines, active irritable bowel syndrome, Lupus, antiphospholipid antibodies, and previous 
VTE (American College of Obstetricians and Gynecologists, 2012; Mitic, 2014). Understanding 
these risks can help patients and providers choose the safest contraceptive method for the 
individual.  
Before choosing a method of contraception, patients must understand their individual risk 
factors to identify and be cautious of potential side effects (American College of Obstetricians 
and Gynecologists, 2012). If women misjudge the safety of CHC use, diagnosis and treatment 
could be deferred because the patient may not take their symptoms seriously or may not report 
using a CHC to a health care provider (Vogt & Scheafer, 2011). The literature suggests 
preventing VTE among CHC users by encouraging women to make educated contraceptive 
decisions (Philipson et al., 2011). However, this is arguably dependent on the prescriber who has 
the responsibility to educate patients about the safety of contraceptives. Although patient 
teaching is necessary for CHC safety, there appear to be barriers to this practice.  
It is concerning that prescribers are not adequately educating patients about contraceptive 
methods. Almost half of women in a study were unable to identify thrombosis and stroke as 
major risks associated with CHC use (Philipson et al., 2011). Almost half of these women also 
claimed not to have been educated about the risks of CHC use prior to having CHCs prescribed 
to them (Philipson et al., 2011). This lack of education by the provider was supported in another 
study where only 1 of 30 participants reported being more knowledgeable about the risks than 
the benefits (Vogt & Scheafer, 2011). This study recommended that providers not worry about 
overwhelming patients with too much information as those who had never used an CHC were 
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found to have the highest interest and lowest knowledge ratings (Vogt & Scheafer, 2011). 
Combined hormonal contraceptives can be taken safely but this relies on appropriate prescribing 
and education by the healthcare provider using an evidence-based guideline. 
Guideline 
The Centers for Disease Control and Prevention (CDC) created the United States Medical 
Eligibility Criteria (U.S. MEC) for contraceptive use to help guide healthcare providers to assess 
patient risk factors and prescribe the safest form of contraception (World Health Organization, 
2009). The U.S. MEC for contraceptive use includes over 1,800 recommendations related to 
more than 60 medical conditions (World Health Organization, 2009). Specifically, this tool helps 
providers identify patient risk factors including age greater than 35 years, tobacco use, 
medications, and certain medical conditions including breast or liver cancer, diabetes, history of 
DVT/PE, migraine headaches, hypertension, and heart disease.  
Utilizing the U.S. MEC for contraceptive use tool promotes evidence based prescribing 
practices and prevents complications associated with contraceptive use (World Health 
Organization, 2009). After evaluating patient risk history, the provider can use the tool to assign 
the patient to a category, one through four, that symbolizes their eligibility for CHC use (World 
Health Organization, 2009). Women with a CHC category 1 condition do not have any 
contraceptive restrictions and can be prescribed the contraception safely. Those with category 2 
conditions also are eligible for CHCs given the benefits outweigh the risks. Combined hormonal 
contraceptive prescription to women with a category 3 condition, however, is deemed 
inappropriate and to category 4 individuals is contraindicated. Category 4 conditions, include 
migraine with aura, history of DVT or stroke, and stage two hypertension. The cardiovascular 
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risks associated with CHC use make it inappropriate to prescribe CHCs to women with category 
3 or 4 conditions, especially given the availability of other contraceptive options. 
Among oral contraceptive pill options, CHCs are the most popular but also have the most 
medical complications including VTE. Other contraceptive methods, including other oral forms, 
are available and are not associated with an increased risk for VTE (World Health Organization, 
2009). Progestin-only pills (POPs) lack the estrogen component making them a safer oral 
contraceptive method for those with medical contraindications for CHC. In addition to POPs, 
other safer contraceptive options include injections, implants, and intrauterine devices (copper-
containing and levonorgestrel-releasing). These methods of contraception provide women with 
long-term birth control, in many cases without the need of a daily pill.  
No matter the contraception method or category, risks and benefits of each option are 
important for the patient and provider to discuss. There is a safe contraceptive method for every 
female who wants to prevent pregnancy. The most crucial aspects of contraceptive safety include 
counseling and follow-up (World Health Organization, 2009). In fact, the U.S. MEC for 
contraceptive use guideline mandates follow-up and contraceptive counseling regarding CHC 
risks and benefits when prescribing to patients with category 2 and 3 conditions (World Health 
Organization, 2009). 
In July 2016, the U.S. MEC for contraceptive use guideline was updated to reflect current  
evidence based practice. The main updates included addition of women with cystic fibrosis, 
multiple sclerosis, and taking St. John’s wort (World Health Organization, 2015). The CHC 
related changes included women with a history of dyslipidemia, migraine headaches, and human 
immunodeficiency virus. When prescribing a CHC, for example, hyperlipidemia was removed as 
a risk, emphasis was made on accurate assessment and documentation of a headache versus 
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migraine with aura, and identification of drug interactions with protease inhibitors and 
antiretrovirals were identified (World Health Organization, 2015). Drug interactions are 
important considerations as these may include increased risk for adverse effects, decreased 
effectiveness of the CHC, and decreased effectiveness of the other, non-contraceptive, 
medication. Notably, the 2016 edition stressed that patients with multiple category 2 and/or 3 
conditions are at increased risk and it is unacceptable for CHC use given the likelihood of 
cardiovascular disease (World Health Organization, 2015). With that said, the 2016 edition also 
stated that the presence of two category 2 conditions does not necessitate a higher risk.  
 
The U.S. MEC guideline is available in many user-friendly tools that are free to the 
public on the CDC website (World Health Organization, 2009). The recommendations are 
summarized in a chart format that is color and number coded to allow for quick reference. 
Guideline recommendations can also be displayed in a wheel format and similar to the pregnancy 
gestation wheel, the inner and outer circles can be rotated to narrow down recommendations for 
the individual (World Health Organization, 2009). The outer circle of the wheel includes medical 
conditions and patient characteristics, while the inner ring consists of contraceptive methods. 
When the wheel is rotated a display window uses the same risk categories, one through four, to 
determine the safest contraceptive option(s) for the patient. Additionally, the guideline can be 
utilized via a cellular phone application that is free to download through the CDC website. Easy 
accessibility is importance for guideline stakeholders.  
 Safe contraception use is a priority for local, state, and worldwide organizations that see 
the economic benefit in addition to the patient benefit. Other stakeholders include patients and 
health care providers. Patients are important stakeholders because they value their health and 
want to choose the safest and most effective contraceptive option. This guideline helps patients 
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avoid contraceptive methods that are riskier, and directs them to the method that is safest for 
them.  Patients have an important role within this guideline because it is the responsibility of the 
patient to disclose their personal, social, and health history, and patient communication is key to 
guideline use and success.  
 Along with patients, health care providers are also key guideline stakeholders because of 
values of maleficence and beneficence. Doctors (MDs), nurse practitioners (NPs), and physician 
assistants (PAs) want to provide patients with contraception that meets their needs, but they also 
do not want their patients to experience potentially lethal complications. Health care providers 
are invested in this guideline because there are several methods and types of contraceptives and a 
helpful evidence based tool is needed. Health care professionals also appreciate the free and 
convenient format for accessibility to the guideline. A guideline that is easy to use is more likely 
to gain compliance.  
The U.S. MEC for contraceptive use guideline had a strong rigor of development that is 
evident from its purpose and historical timeline. The CDC and WHO have worked together to 
create the U.S. MEC for contraceptive use and its purpose is to be used by policy makers to 
promote family planning at the national and global level (World Health Organization, 2009). 
Since the first edition of the contraceptive guideline that was released in 1996, there have been 
five revisions to reflect the most recent literature. This guideline can stand-alone but is 
strengthened by a similar guideline also developed by the CDC.  
A sister guideline titled the U.S. Selected Practice Recommendations for Contraceptive 
Use (U.S. SPR) was created in 2013 and recommends how to overcome barriers for obtaining 
and appropriately using contraceptive options (World Health Organization, 2009). Specific 
recommendations from the U.S. SPR include when to initiate contraception (rule out pregnancy), 
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use backup contraception, which tests are needed prior to taking contraception, and what follow-
up is needed to maintain contraceptive safety. In addition to the CDC and WHO, the U.S. SPR 
guideline is also supported by the American Congress of Obstetricians and Gynecologists 
organization.  
Project 
Aims 
It is important for prescribers to assess patients for risk factors of developing complications 
from CHCs and counsel regarding the safest method of contraception. The aim of this project 
was to examine contraceptive counseling and prescribing behaviors and compare these behaviors 
with the recommendations set forth by the U.S. MEC for contraceptive use guideline. The aims 
of this project helped to identify guideline adherence with guideline recommendations. The 
specific aims this project accomplished include:  
1. To assess rates of prescriber documentation of risk factors (age, smoking, medications, and 
medical history and conditions) associated with combined contraceptives.  
2. To assess frequency of prescriber documentation of using a combined contraceptive that is 
considered safe by the U.S. MEC for contraceptive use guideline. 
3. To assess rates of prescriber documentation of combined contraceptive counseling and 
follow-up.  
Study Design 
This was a descriptive study that examined provider adherence to the U.S. MEC for 
contraceptive use guideline when prescribing CHCs within a set of mid-west, university-based, 
primary health care clinics. It included a retrospective, cross-sectional chart review of 100 charts 
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that met inclusion and exclusion criteria. After approval was gained from the university’s 
Institutional Review Board, the primary investigator worked with the university’s Center for 
Clinical and Translational Sciences program to create a list of patient charts that met this study’s 
criteria. Review of charts helped meet the aims of this study by identifying the safety of CHC 
prescription practices.  
Patient age, provider type (MD, PA, or NP), and length of tenure were recorded. Length 
of tenure was determined by comparing the date the chart was written with the provider’s 
graduation date found on the university website. Additional recorded variables were prescriber 
documentation of risk factors (age, smoking, medications, and medical history and conditions) 
associated with combined contraceptives, documentation of prescribing a combined 
contraceptive that is considered safe by the U.S. MEC for contraceptive use guideline, and lastly, 
documentation of contraceptive counseling and follow-up.  
Study Population 
Inclusion criteria included the following charts: service dates from August 1, 2014 to 
August 1, 2016, reviewed by the principal investigator from December 10, 2016 to April 1, 2017, 
prescribed by an MD, PA, or NP.  Selected charts were also from non-pregnant females between 
the ages of 18 and 50 years of age. Charts included those that prescribed a CHC, were coded for 
encounter for contraceptive management (ICD-10 code Z30 or ICD-9 code V25), and had at 
least one (category 2, 3, or 4) risk for CHC use per the U.S. MEC for contraceptive use 
guideline. Additional inclusion criteria were identified with ICD-9 and ICD-10 codes that 
reflected a diagnosis of a category 2, 3, or 4 risk factor (see Table 1).  
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Methods 
As part of routine patient care, clinic personnel had previously recorded the pertinent 
patient data that was used for this chart review. The primary outcome measure was guideline 
adherence. Primary outcome measures included the following: 
1. Documented pertinent patient information including age, tobacco use, current and past 
medical history, current medications, and last pregnancy or hospitalization.  
2. Did not prescribe a CHC if the patient had a category 4 condition as defined by the U.S. 
MEC for contraceptive use guideline. 
3. Documented follow-up if the patient had a category 2 or 3 condition, as defined by the 
U.S. MEC for contraception use guideline. 
4. Documented contraceptive counseling for patients with category 2 or 3 conditions, as 
defined by the U.S. MEC for contraceptive use guideline (patient teaching of CHC risks 
and/or adverse effects).  
The secondary outcome measures were provider and patient specific variables. Provider 
variables included type of provider and practice tenure. Patient variables included age and 
condition.  
This project’s focus on guideline adherence was measured by inappropriate and 
contraindicated prescribing, and the use of follow-up and contraceptive counseling. Inappropriate 
prescribing was characterized if a category 3 condition was present where the risks generally 
outweigh the benefits, and contraindicated prescribing was determined if a category 4 condition 
was present. The contraceptive guideline does not support prescription of a CHC to women with 
a category 4 condition, and mandates follow-up and contraceptive counseling when prescribing a 
CHC to women with a category 2 or 3 condition (World Health Organization, 2009). Therefore, 
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complete guideline adherence was observed for charts that did not contain a category 4 condition 
and documented both follow-up and contraceptive counseling. Partial guideline adherence was 
measured if the chart lacked a category 4 condition and documented either contraceptive 
counseling or follow-up, and finally, no guideline adherence was defined as lack of both follow-
up and contraceptive counseling. 
Data Analysis 
Descriptive statistics were used to summarize the study sample (see Table 2). To test for 
differences in degree of completeness by patient age and provider type, Spearman’s rho 
correlation coefficient was used. The Mann-Whitney U test was used to compare differences in 
completeness by provider type (see Table 3). All data analysis was conducted using SPSS, 
version 24, and an alpha level of .05 was used throughout. Data was analyzed using the SPSS 
computer program to determine the proportion of charts that successfully documented all three 
aims. Chi-square analysis was used to assess differences among groups of providers and patients 
who participated in inappropriate use of CHC. This information, along with the results, was used 
to identify barriers to safe prescribing of CHCs.      
Results 
One hundred charts from mid-west, university based, primary care clinics that met 
inclusion and exclusion criteria were reviewed. Of the 100 charts, 66 were written by MDs 
(66%) and 34 were authored by Advanced Practice Providers (APPs; 34%). Among the 34 charts 
written by APPs, 26 were by NPs, and eight were by PAs. The patients’ ages ranged from 18 to 
49 years with a mean age of 26.67 years (SD=7.073). Provider tenure was categorized into 
intervals, zero to three years, four to five years, six to ten years, and over ten years, and tenure 
frequency was 20%, 28%, 24%, and 28% respectively (see Table 1).  
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Category 4 
Four charts contained category 4 conditions (four percent) where CHCs were prescribed 
despite the presence of a contraindication. Among these four charts, all were written by MDs 
with a tenure that varied from one to ten years. Among charts with category 4 risks, patients’ 
ages ranged from 20 to 30 years and category 4 conditions included Lamictal use, migraine with 
aura, and history of stroke. Migraine with aura was the most frequent category 4 condition that 
was prescribed a CHC, accounting for half of category 4 charts. Although three fourths of 
category 4 charts did recommended follow-up, all four charts did not document contraceptive 
counseling. Lastly, a quarter of charts with contraindicated CHC prescription did not document 
counseling or recommend follow-up.  
Category 3 
Fifteen charts contained category 3 conditions (15%), and listed by highest frequency 
included hypertension (53%), migraine with no aura (20%), smoking and 35 years or older 
(13%), and finally diabetes with neuropathy and malabsorptive surgery (7% each). Among the 
15 charts with category 3 conditions, or inappropriate prescribing conditions, 80% were written 
by MDs while 20% were prescribed by APPs. In a comparison of guideline adherence 
completeness by the most common category 3 conditions, the Mann-Whitney U test was utilized, 
and found that both hypertension and migraine without aura had insignificant p-values (p=.78 
and .33 respectively).  
Category 2 
Category 2 conditions were the most prevalent risk category accounting for 81% of all 
100 charts. The most frequent category 2 conditions were obesity (42%), smoking less than 35 
years of age (31%), and headaches (five percent). In a comparison of completeness by the most 
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common category 2 conditions using the Mann-Whitney U test, p-values for smoking (less than 
35 years of age) and obesity were not significant (p=.20 and .37 respectively).  
Completeness 
The charts that contained category 4 conditions were eliminated from guideline 
adherence analysis due to the presence of a complete contraindication for CHC use. Among the 
remaining 96 charts that contained category 2 and 3 conditions, 28% recommended both follow-
up and contraceptive counseling fulfilling complete guideline adherence. Forty nine percent of 
charts met one of the requirements, and had partial adherence, and finally 23% of charts lacked 
both follow-up and contraceptive counseling and had zero guideline compliance. A comparison 
of follow-up and contraceptive counseling, revealed that among charts with category 2 and 3 
conditions, 69% recommended follow-up and 36% documented contraceptive counseling.  
Completeness by Provider Type 
Complete guideline adherence was observed for charts that did not contain a category 4 
condition and documented both follow-up and contraceptive counseling. Among the 27 charts 
that exhibited complete guideline adherence, over half were written by MDs (56%) compared 
with 44% that were authored by APPs. No guideline adherence was defined as lack of both 
follow-up and contraceptive counseling. Among the 22 charts with no guideline compliance, 
over half were written by APPs (55%) compared to 45% of MDs. Of the charts that documented 
follow-up, 71% were written by MDs and only 29% were by APPs. This comparison between 
MD provider type and follow-up was significant with a chi-square of 4.1 (p=.044). Of the charts 
that documented contraceptive counseling, 57% were written by MDs, and 43% were by APPs 
and this was not significant (chi-square 0.25). 
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Completeness by Patient Age and Provider Tenure 
The Mann-Whitney U test was used to compare differences in guideline compliance 
completeness by provider type (see Table 2) and was not significant with a chi-square of 0.2. 
Spearman’s rho test was used to compare tenure and completeness, and was not significant at 
0.39. There was also no difference in degree of completeness by patient age (rho=-0.11; p=.30), 
provider type (Chi-square=0.21; p=.65) or provider tenure (rho=-0.09; p=.39; see Table 2).  
Completeness by Patient Condition 
An association among the top five most frequent category 2 and 3 conditions (obesity, 
smoking, migraine with no aura, hypertension, and headaches) and completeness was not 
significant. However, obese patients were most likely to not receive any guideline adherence 
(29%), and patients with migraine and no aura were more likely to receive complete guideline 
adherence (36%). Thirty-one percent of charts with smoking had complete adherence and 25% of 
charts with hypertension had complete compliance. Of note, nine single conditions were not 
coded (Lamictal, history of stroke, valvular heart disease, malabsorptive bariatric surgery, 
Rheumatoid Arthritis, post-partum, Ulcerative Colitis, diabetes with neuropathy, family history 
of clot) and therefore not included in analysis of completeness by condition. 
Limitations 
The major limitations of this study were sample and information bias. The small sample 
size of 100 charts made it difficult to account for differences in variables like provider type and 
tenure. Additionally, the patients and providers included in this study were restricted to a 
university-based healthcare system located in the mid-west creating a more homogenous sample 
with weaker associations. The retrospective nature of this study also did not allow for a 
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comparison group to estimate the importance of risk factors (especially over time). Also true to a 
retrospective study, this chart review did not have the ability to control for accurate assessment 
and documentation within the electronic medical record (EMR).  
Additional imitations of this study revolve around the use of the EMR. Only one type of 
EMR was utilized by this study, preventing comparison with other types of EMR. This particular 
EMR did not have automatic prompts regarding contraceptive counseling and follow-up that 
other EMR versions might enlist. Additionally, this EMR did not assess the quantity of cigarette 
use per day. The quantity of cigarettes is an important indicator of CHC related thrombotic risk 
under the U.S. MEC for contraceptive use guideline (World Health Organization, 2009). The 
EMR failed to prompt providers to quantify daily tobacco use when adding “Current everyday 
smoker” to a list of active problems. With that said, providers also frequently failed to document 
quantity of cigarette use per day in narration.  
This study was also limited by not accounting for initiation versus continual use of CHC. 
This is significant to the guideline due to the increased risk of adverse effects within the first 
three months of use. It is estimated that venous thrombotic risks increase three-fold following 
initiation of a CHC due to adjustments in hormone levels that impact coagulation (Han & Jensen, 
2015).  
Discussion 
This retrospective chart audit sought to describe adherence and CHC prescribing safety 
using a reputable national guideline. This study found that 19% percent of women were 
prescribed a CHC inappropriately, including four percent of patients with a category 4 
contraindication to CHC use. This study found the most common risks included obesity, 
smoking, migraine (with and without aura), and hypertension. Compared to a much larger but 
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similar study, of 2,963 women, 33% were inappropriately prescribed a CHC, nine percent 
possessed category 4 risks, and the most common risk conditions included migraine (with and 
without aura), cardiovascular disease, and hypertension (Yu & Hu, 2013). Although the results 
of this study reflected better guideline adherence than the comparison study, the findings from 
both demonstrate the need for stricter compliance to prevent complications associated with 
contraceptive use. Identifying barriers to safe prescribing can help promote guideline 
compliance.  
While most of the comparisons in this study were not significant, across all variables a 
major barrier to safe prescribing of CHC is lack of knowledge. MDs, PAs, and NPs were almost 
equally poor at completing contraceptive counseling, and achieving guideline adherence. 
Although less than a quarter of charts had no guideline adherence, only a little over a quarter had 
full compliance. Most important to discuss regarding guideline adherence and knowledge gaps 
were the four charts (4%) that prescribed a CHC in the presence of a category 4 condition.  
Although charts with category 4 conditions accounted for only four percent of charts, 
prescribing a CHC in these instances is deemed “unacceptable” by the guideline and these charts 
deserve a closer evaluation (World Health Organization, 2009). In addition, the prevalence of 
prescribing a CHC to a patient who is obese, smokes, or has a history of migraines (with or 
without aura) or hypertension also requires discussion. These four CHC risk conditions are 
discussed more in-depth to help bridge these knowledge gaps.  
Obesity 
The first condition associated with a lack of provider comprehension when prescribing a 
CHC was obesity. Obesity is defined as a Body Mass Index of 30, kilograms per meter squared, 
or more and is classified as a category 2 condition under the U.S. MEC for contraceptive use 
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guideline (World Health Organization, 2009). In this study, obesity was a common condition 
with infrequent follow-up and contraceptive counseling. Obesity was the most frequent condition 
accounting for 44% of all conditions and 29% of obese patients did not receive follow-up or 
contraceptive counseling. Although only a category 2 condition, VTE risk has been shown to 
increase with degree of obesity (Horton, Simmons, & Curtis, 2016). In fact, five prospective 
cohort studies found a dose-response relationship between obesity and VTE risk (Horton, 
Simmons, & Curtis, 2016). Furthermore, obese CHC users were five to eight times more likely 
to experience VTE than obese non-users, and obese CHC users were also ten times more likely 
to experience VTE than normal weight users (Horton, Simmons, & Curtis, 2016).  
Smoking 
The second condition associated with a lack of provider comprehension when prescribing a 
CHC was smoking. Smoking restrictions among CHC users date back to 1989 when the FDA 
modified their CHC restrictions and allowed women of all ages to use CHC as long as they did 
not smoke (Food and Drug Administration, 2012). Under the U.S. MEC for contraceptive use 
guideline, smoking is a risk condition for CHC use that ranges from two to four due to its 
influence on cardiovascular disease (CVD; World Health Organization, 2009). Smoking is a 
category 2 condition for CHC use if the patient is less than 35 years of age. For women who are 
35 years or older, smoking is a category 3 condition if use is less than 15 cigarettes per day, and 
finally, smoking is a category 4 condition if the female smokes 15 or more cigarettes per day.  
In this study, smoking was a common condition with infrequent follow-up and 
contraceptive counseling. Women who smoked and were less than 35 years of age accounted for 
31% of category 2 conditions, and females who smoked and were 35 years or older made up 
13% of all category 3 conditions. Of importance, only 31% of charts with smoking (age less than 
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35 years) had complete adherence with documentation of both follow-up and contraceptive 
counseling. These shortcomings are significant because compared to non-smokers, CHC users 
who smoke are at risk for a heart attack and this risk increases with the number of cigarettes 
smoked per day (Nightingale et al., 2000). It is argued that health care providers can help prevent 
VTEs among patients who use OCPs by focusing on tobacco cessation (Grimes et al., 2012). 
Headaches/Migraines 
The third condition where providers lacked an understanding of CHC safety was 
headaches/migraines. Under the U.S. MEC for contraceptive use guideline, non-migrainous 
headaches are classified as a category 2 condition for CHC use, migraines without aura are a 
category 3 condition if the woman is 35 years or older, and finally migraine with aura (no matter 
the age) is a category 4 condition for CHC use (World Health Organization, 2009). Headaches 
were five percent of category 2 conditions, migraine with no aura accounted for 20% of category 
3 charts, and migraine with aura made up half of charts with a category 4 contraindications to 
CHC use.  
Migraines with aura are often overlooked as important contributors to cardiovascular 
disease (CVD) and VTE. Migraines with aura are associated with an increased risk for stroke due 
to changes in cortical depression, and likelihood of underlying genetic and co-morbid conditions 
(Kurth et al., 2006; Pezzini et al., 2009). In a study by the WHO that examined stroke among 
women of childbearing age, the risk for stroke was significantly related to the frequency of 
migraines with aura, and the risk of stroke was increased among CHC users, compared with 
women not using CHCs (Etminan, Takkouche, Isorna, & Samii, 2005). Cardiovascular disease is 
the major contributor of stroke and heart attack, and compared to women without migraines, 
women who experienced migraine with aura once a month were two times more likely to 
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develop CVD, and those with migraine with aura two or more times per week were four times 
more likely to develop CVD (Donaghy, Chang, & Poulter, 2002). 
Hypertension 
The final CHC condition where providers displayed a knowledge deficit was 
hypertension. Hypertension during pregnancy is deemed a category 2 condition for CHC use, 
and hypertension is a category 3 condition if it is adequately controlled by medication or is less 
than 160 systolic over 100 diastolic (160/100; World Health Organization, 2009). Hypertension 
is a category 4 condition if blood pressure measurement is 160/100 or more and a CHC is 
contraindicated (World Health Organization, 2009). Fifty-three percent of category 3 conditions 
were hypertension and only 25% of charts with hypertension had complete compliance. 
Hypertension is an important risk condition for providers to consider because the U.S. MEC for 
contraceptive use guideline found that women with hypertension who used CHCs were more 
prone to stroke, heart attack, and peripheral arterial disease compared with nonusers (Gillum, 
Mamidipudi, & Johnston, 2000; Khader, Rice, John, & Abueita, 2003). Furthermore, women 
with hypertension who stopped CHC use experienced better blood pressure control (Lubianca, 
Moreira, Gud, & Fuchs, 2005).  
Follow-up and Counseling 
The U.S. MEC for contraceptive use guideline mandates follow-up and contraceptive 
counseling regarding CHC risks and benefits when prescribing to patients with category 2 and 3 
conditions (World Health Organization, 2009). Thus, when prescribing a CHC to a patient with 
category 2 and 3 risks, the provider must consider availability, acceptability, and access to 
clinical services. Using clinical judgment, the provider must assess these patient variables and 
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proceed with caution when prescribing a CHC to a woman with a history of appointment 
cancelations, no-shows, or with limited access to resources.  
A guiding principle of the U.S. MEC for contraceptive use guideline is the patient’s right 
to choose and make an informed decision and this encompasses contraceptive counseling (World 
Health Organization, 2009). The health care provider is the most important facilitator of this goal 
by emphasizing the serious risk of a thrombotic event while using a CHC. When providers teach 
patients about thrombotic risk factors, patients have the opportunity to modify their actions and 
prevent acquisition of new risks. Additionally, a patient who is taught about adverse effects of 
using a CHC, will not underestimate the severity and promptness if symptoms of a thrombotic 
event presents.  
Counseling techniques are patient specific and can be divided into initiation and 
continuation. Important topics to consider with new users include mechanism of action, 
advantages and disadvantages of different contraceptive methods (including non-contraceptive 
benefits), warning signs of adverse effects, misconceptions, and need for follow-up (Wysocki, 
1998). Important discussion points with follow-up and continual prescription of CHC includes 
identification of new symptoms or health problems, and reiteration of the increased risk of a 
thrombotic event while using a CHC and the risk factors that amplify this risk.   
Conclusion 
The U.S. Medical Eligibility Criteria for contraceptive use guideline helps healthcare 
providers to assess patient risk factors and prescribe the safest form of contraception. Utilizing 
this tool can help promote evidence based prescribing practices and assist in preventing 
complications associated with contraceptive use. Additionally, safe prescribing practices can also 
promote family planning and prevent unplanned pregnancies at the local level. Although this 
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study only found one strong comparison, it is concluded that all types of healthcare providers can 
better promote contraceptive safety by using the contraceptive guideline and utilizing thorough 
contraceptive counseling and timely follow-up. The patient has a right to make an informed 
decision and prevent health risks and a provider who utilizes the contraceptive guideline can 
facilitate patient and contraceptive safety.  
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Table 1: Inclusion and Exclusion Criteria 
Inclusion Exclusion 
- Encounter for contraceptive management (ICD-10 code Z30 or ICD-9 code V25) 
- Family history of DVT or PE, current or personal history of DVT or PE (ICD-10 code 
Z86.718, I82, ICD-9 code V12.51) 
- Recent surgery requiring immobilization 
- Breast cancer (ICD-10 code C50, ICD-9 code 174) 
- Currently breastfeeding (ICD-10 code Z39.1 and ICD-9 code V24.1) 
- Gallbladder disease (ICD-10 code K82.8, K82.9, ICD-9 code 575.9), 
- Headaches or migraines (ICD-10 code R51, G43, ICD-9 code 339, 784, 346.9) 
- Sickle cell disease (ICD-10 code D57, ICD-9 code 282) 
- Ischemic heart disease (IDC-10 codes I25.9 and I24.9, ICD-9 code 414.9) 
- Benign or malignant liver tumor (ICD-10 code D13.4, ICD-9 code 211.5) 
- Diabetes (ICD-10 code E10 and E11, ICD-9 code 250.80 and 250.81), 
- Tobacco use (ICD-10 code Z72.0, ICD-9 code 305.1), 
- Hypertension (ICD-10 codes I10, I15, and O13, ICD-9 codes 401.0, 401.9, 405.91, 
405.99, 642.3), 
- Hyperlipidemia (ICD-10 code E78.5, ICD-9 code 272) 
- Obesity (ICD-10 code E66, ICD-9 code 278) 
- Untreated cervical cancer (ICD-10 code  Z85.41 and C53, ICD-9 code V10.41), 
- Ulcerative colitis and Chron’s disease (ICD-10 code K51, ICD-9 code 556) 
- Rheumatoid arthritis (ICD-10 code M05, ICD-9 code 714) 
- Organ transplant (ICD-10 code Z94, ICD-9 code V42) 
- Stroke or TIA (ICD-10 code Z86.73, ICD-9 code V12.54) 
- Lupus/SLE (ICD-10 code M32.1, ICD-9 code 710), 
- Thrombogenic mutation (ICD-10 code D68, ICD-9 code 289.81), 
- Valvular heart disease (ICD-10 code I06, I07, ICD-9 code 397.1), 
- Viral hepatitis (ICD-10 code B15-B19, ICD-9 code 070.1). 
- Less than 18 years of age 
or more than 50 years of 
age 
- Diagnosis of pregnancy 
- Not prescribed a CHC 
- Not written by an MD, 
PA, or NP  
- Written or reviewed 
outside the time 
parameters 
- No medical conditions 
including no category 2, 
3, or 4 conditions for 
CHC use 
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Table 2: Study Population Demographics 
 Mean (SD) or n (%) 
Patient age 26.67 (7.073) 
Provider type 
- MD 
- APP 
o NP 
o PA 
 
66 (66%) 
34 (34%) 
26 (26%) 
8 (8%) 
Conditions (category) 
- Obesity (2) 
- Smoking (2-4*) 
- Migraine, no aura (2-3*) 
- Hypertension (3-4*) 
- Headaches (0-2*) 
- Hyperlipidemia (0-3*) 
- Cholecystectomy (2) 
- DM, no complications (2) 
- Migraine, with aura (4) 
* Smoking: Age <35 = Category 2; age 35+ and <15 
cigs/day = Category 3; age 35+ and 15+ cigs/day = 
Category 4. Migraine, no aura: Age <35 = Category 2; 
age 35+ = Category 3. Hypertension: <160/100 or 
medically controlled = Category 3; 160/100+ = 
Category 4. Headaches 2012 = Category 2. 
Hyperlipidemia 2012: Category 3.  
Nine single conditions not coded (Lamictal, CVA 
history, valvular heart disease, malabsorptive surgery, 
RA, post-partum, UC, DM with neuropathy, family 
 
42 (43.75%) 
31 (32.39%) 
22 (22.92%) 
8 (8.33%) 
5 (5.21%) 
3 (3.13%) 
3 (3.13%) 
2 (2.08%) 
2 (2.08%) 
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history of clot; all conditions n=1).  
Provider tenure (years) 
- 0-3 
- 4-5 
- 6-10 
- >10	
 
18 (20.22) 
25 (28.09) 
21 (23.60) 
25 (28.09) 
Completeness 
   Complete 
   Partial 
   None 
 
27 (28.13%) 
47 (48.96%) 
22 (22.92%) 
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Table 3: Comparison of Patient Age, Provider Type, and Provider Tenure by Completeness 
 Complete  
Both F/U and CC 
(n=27) 
Partial  
Either F/U or CC 
(n=47) 
None  
Neither F/U nor CC 
(n=22) 
p 
Patient age 25.9 (6.6) 26.3 (6.7) 28.7 (8.5) .30 
Provider type 
   NP/PA 
   MD 
 
12 (44.4%) 
15 (55.6%) 
 
10 (21.3%) 
37 (78.7) 
 
12 (54.5%) 
10 (45.5) 
.65 
Provider tenure 
(years) 
0-3 
4-5 
6-10 
>10 
 
 
7 (26.92) 
4 (15.38) 
9 (34.62) 
6 (23.08) 
 
 
9 (20.00) 
16 (35.56) 
6 (13.33) 
14 (31.11) 
 
 
2 (11.11) 
5 (27.78) 
6 (33.33) 
5 (27.78) 
 
.39 
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